Regdanvimab: First Approval
Tóm tắt
Regdanvimab (Regkirona™) is a recombinant human monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus 2. It is being developed by Celltrion Inc. for the treatment of coronavirus disease 2019 (COVID-19). In September 2021, regdanvimab received full approval in South Korea for the treatment of COVID-19 in elderly patients aged > 50 years with at least one underlying medical condition (obesity, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients on immunosuppressive agents) and mild symptoms of COVID-19 and in adult patients with moderate symptoms of COVID-19. This article summarizes the milestones in the development of regdanvimab leading to this first approval for COVID-19.
Tài liệu tham khảo
European Medicines Agency. Celltrion use of regdanvimab for the treatment of COVID-19: assessment report. 2021. https://www.ema.europa.eu/en/documents/referral/regdanvimab-treatment-covid-19-celltrion-covid-19-article-53-procedure-assessment-report_en.pdf. Accessed 1 Oct 2021.
Kim C, Ryu DK, Lee J, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun. 2021;12(1):288.
Celltrion. Celltrions monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS) [media release]. 18 Sep 2021. http://www.celltrionhealthcare.com.
Ministry of Food and Drug Safety. Regdanivmab full Korean approval. 2021. https://www.mfds.go.kr/brd/m_99/view.do?seq=45778. Accessed 11 Oct 2021.
European Medicines Agency. EMA receives application for marketing authorisation for Regkirona (regdanvimab) for treating patients with COVID-19. 2021. https://www.ema.europa.eu/en/news/ema-receives-application-marketing-authorisation-regkirona-regdanvimab-treating-patients-covid-19. Accessed 11 Oct 2021.
European Medicines Agency. Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for unauthorised product Regkirona (regdanvimab). 2021. https://www.ema.europa.eu/en/documents/referral/celltrion-use-regdanvimab-treatment-covid-19-article-53-procedure-conditions-use-conditions_en.pdf. Accessed 22 Sep 2021.
European Medicines Agency. EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19 [media release]. 24 Feb 2021. http://www.ema.europa.eu.
European Medicines Agency. EMA issues advice on use of regdanvimab for treating COVID-19. 2021. https://www.ema.europa.eu/en/news/ema-issues-advice-use-regdanvimab-treating-covid-19. Accessed 11 Oct 2021.
Celltrion. Celltrion Healthcare announces acceptance and priority review by Health Canada of New Drug Submission for its monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) [media release]. 2 Aug 2021. http://www.celltrionhealthcare.com.
Therapeutic Goods Administration. TGA grants provisional determination to Celltrion Healthcare Australia Pty Ltd’s antiviral COVID-19 treatment regdanvimab [media release]. 23 Aug 2021. www.tga.gov.au.
Celltrion. Celltrion develops tailored neutralising antibody cocktail treatment with CT-P59 to tackle COVID-19 variant spread using its antibody development platform [media release]. 11 Feb 2021. http://www.celltrionhealthcare.com.
Inhalon Biopharma. Inhalon doses first patient in phase 1 study of inhaled IN‑006 to treat COVID-19 [media release]. 7 Oct 2021. https://www.inhalon.com/07october2021.
Inhalon Biopharma. Inhalon collaborates with Celltrion, Inc. to develop nebulized form of regdanvimab to treat COVID-19 patients at home [media release]. 22 Jul 2021. http://www.inhalon.com.
Ryu DK, Kang B, Noh H, et al. The in vitro and in vivo efficacy of CT-P59 against gamma, delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun. 2021;578:91–6.
Ryu DK, Song R, Kim M, et al. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochem Biophys Res Commun. 2021;566:135–40.
Kim JY, Jang YR, Hong JH, et al. Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection. Clin Ther. 2021. https://doi.org/10.1016/j.clinthera.2021.08.009.
Eom JS, Ison M, Streinu-Cercel A, et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. Res Sq. 2021. https://doi.org/10.21203/rs.3.rs-296518/v1.
Celltrion. Celltrion announces positive top-line results from global phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment [media release]. 14 Jun 2021. http://www.celltrionhealthcare.com.
Kreuzberger N, Hirsch C, Chai KL, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021. https://doi.org/10.1002/14651858.CD013825.pub2.
Heo J, Park S, Je NK, et al. Effectiveness and safety of regdanvimab in patients with mild-to-moderate COVID-19: a retrospective cohort study. Nat Portf. 2021. https://doi.org/10.21203/rs.3.rs-846378/v1.